Cannara Biotech, as highlighted by Research Capital analyst Greg McLeish, exhibited impressive performance in its fiscal third quarter, surpassing revenue and operating expectations. With reported revenue of $27.3 million for the period ending May 31, 2025, the company outperformed forecasts and demonstrated substantial growth compared to the previous year. Notably, the gross margin of 44% exceeded estimates, reflecting enhanced production capabilities and operational efficiencies. Adjusted EBITDA also saw a significant increase, reaching $7.6 million and more than doubling year-over-year, while net income of $4.1 million surpassed projections.
McLeish emphasized Cannara’s strategic approach to expanding its production platform through a disciplined, modular strategy, effectively doubling its current capacity with a modest capital investment of $22 million. Through focused research and development efforts and cultivation optimizations, the company achieved a remarkable 26% increase in yield, elevating its annual production capacity to 50,000 kg ahead of schedule. Moreover, Cannara revised its production targets upward for future years, aiming for 65,000 kg in F2027 and 80,000 kg in F2028. The Valleyfield facility, upon full build-out, is designed to support up to 100,000 kg of annual output, providing significant capacity for future scalability.
Looking ahead, Cannara plans to finalize a $10 million processing center at its Valleyfield facility during fiscal 2026, enhancing its operational capabilities across multiple grow rooms. McLeish highlighted the potential growth catalyst of the expected legalization of cannabis vape cartridges in Quebec by late 2025, identifying an opportunity for Cannara to capitalize on strong consumer demand. With the preliminary approval of vape SKUs for province-wide distribution, Cannara’s leading market position in live resin vapes positions it favorably to leverage this new category within its core provincial market.
McLeish’s analysis projects Cannara to achieve $25.1 million in Adjusted EBITDA on revenue of $104.0 million in fiscal 2025, with anticipated improvements to $33.7 million in Adjusted EBITDA and $121.2 million in revenue in fiscal 2026. The unchanged “Buy” rating and $3.00 target price are supported by Cannara’s efficient operations in Quebec, vertical integration, and successful execution of premium products. The target valuation is based on an 8.0x FY2027 EBITDA multiple, reflecting confidence in Cannara’s future performance and market positioning.
Key Takeaways:
– Cannara Biotech demonstrated robust financial performance in its fiscal third quarter, surpassing revenue and operating expectations.
– The company’s strategic focus on production expansion and operational efficiencies has led to significant increases in yield and capacity.
– Anticipated growth opportunities, such as the potential legalization of cannabis vape cartridges in Quebec, position Cannara favorably for future market expansion.
– Analyst projections suggest continued financial strength for Cannara, supported by its operational excellence and premium product offerings.
Read more on cantechletter.com